Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in Advanced/Metastatic Solid Tumors
NCT06115642Phase 1Enrolling by invitation
- Sponsor
- Henlius
- Start
- Nov 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of HLX43 in solid tumor, non-small cell lung cancer (NSCLC) and thymic carcinoma (TC) (5 arms), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days, Objective Response Rate at 24 months and 2 more. Started Nov 2023; status: enrolling by invitation.
02
Drugs
HLX43
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT06115642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115642.